RoosterBio
Supplier of standardized human primary cell systems, xeno-free media, reagents, and bioprocess workflows to support translation and scale-up of mesenchymal stromal/stem cell (MSC) and extracellular vesicle (EV) development. Provides cryopreserved cell banks, bioreactor feed strategies, analytical characterization, process development services, and documentation to support clinical manufacturing and regulatory submissions.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Cryopreserved primary hMSC starter kits (research and xeno‑free formats)
Starter kits containing cryopreserved human MSC vials and expansion media with supplied expansion protocols for rapid in vitro expansion and process optimization; available in multiple tissue sources and xeno‑free formats.
Cell culture media and supplements (xeno‑free, GMP‑compatible)
Media systems, boosters, and concentrated feeds formulated for MSC expansion and EV production, with research and GMP‑compatible options to support scale translation and fed‑batch bioreactor workflows.
EV production reagents and collection supplements
Reagent(s) and low‑particulate collection media components designed to boost EV/conditioned medium collection yields and support scalable EV workflows integrated with isolation strategies.
Growth factors, cytokines, and formulation components
Catalog of recombinant growth factors, cytokines, and supplement components for media formulation and process development.
cGMP‑compatible clinical control cell banks
Clinical‑grade control cell bank products and related QC documentation intended to support clinical manufacturing comparators and regulatory filings.
Cryopreserved primary hMSC starter kits (research and xeno‑free formats)
Starter kits containing cryopreserved human MSC vials and expansion media with supplied expansion protocols for rapid in vitro expansion and process optimization; available in multiple tissue sources and xeno‑free formats.
Cell culture media and supplements (xeno‑free, GMP‑compatible)
Media systems, boosters, and concentrated feeds formulated for MSC expansion and EV production, with research and GMP‑compatible options to support scale translation and fed‑batch bioreactor workflows.
EV production reagents and collection supplements
Reagent(s) and low‑particulate collection media components designed to boost EV/conditioned medium collection yields and support scalable EV workflows integrated with isolation strategies.
Growth factors, cytokines, and formulation components
Catalog of recombinant growth factors, cytokines, and supplement components for media formulation and process development.
cGMP‑compatible clinical control cell banks
Clinical‑grade control cell bank products and related QC documentation intended to support clinical manufacturing comparators and regulatory filings.
Services
Contracted support for upstream culture process development, CPP/CQA establishment, analytical method development, EV/cell characterization, and scale‑up planning to support translation to clinical manufacturing.
Contracted support for upstream culture process development, CPP/CQA establishment, analytical method development, EV/cell characterization, and scale‑up planning to support translation to clinical manufacturing.
Expertise Areas
- MSC biomanufacturing and scale-up
- Extracellular vesicle bioproduction and downstream processing
- Fed‑batch microcarrier suspension bioreactor processes
- Xeno‑free media and bioreactor feed formulation
Key Technologies
- Microcarrier suspension bioreactors
- Fed‑batch bioreactor feed strategies
- Tangential flow filtration (TFF)
- Ultracentrifugation for particle isolation
News & Updates
Recipient of the Stem Cell Innovation Catalyst Award from the Maryland Stem Cell Research Commission.
Received the Maryland Stem Cell Research Commission (MSCRF) Commercialization Award.
Named Emerging Life Science Company of the Year by the Maryland Tech Council.
Included in Top 50 Manufacturers by Frederick County Office of Economic Development / Frederick Magazine.
Raised $15 million in an initial Series B funding round.
Recipient of the Stem Cell Innovation Catalyst Award from the Maryland Stem Cell Research Commission.
Received the Maryland Stem Cell Research Commission (MSCRF) Commercialization Award.
Named Emerging Life Science Company of the Year by the Maryland Tech Council.
Included in Top 50 Manufacturers by Frederick County Office of Economic Development / Frederick Magazine.
Raised $15 million in an initial Series B funding round.